trending Market Intelligence /marketintelligence/en/news-insights/trending/tqpAuyBq0MY2Yj0qm-EqPg2 content esgSubNav
In This List

US FDA to expedite Mesoblast's heart failure treatment in patients with implants

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


US FDA to expedite Mesoblast's heart failure treatment in patients with implants

Mesoblast Ltd's approval application for its mesenchymal precursor cell, or MPC, therapy has been expedited as the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to the product.

The MPC therapy aims to treat heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices.

The designation also allows for priority review of the therapy.

The U.S. FDA granted the designation based on the preliminary results of a placebo-controlled trial. The study reported improved heart function and improved survival rates in patients with heart implants along with a delay in internal bleeding caused by the same.

Mesoblast is conducting a phase 2b trial for the product. The company expects to have results from the trials by the first quarter of 2018.